This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
IMF Predicts Strong GDP Growth for India: Stocks in Focus
by Zacks Equity Research
Strong growth in the Indian economy should aid stocks from this region.
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
by Zacks Equity Research
Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong
by Zacks Equity Research
Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.
Indian Stocks in Focus as IMF Appreciates Its Economic Growth
by Nalak Das
According to the IMF, Indian economy is gaining momentum as a result of several policy reforms taken by Prime Minister Narendra Modi's administration.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for BICK
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Company News For Jun 18, 2018
by Zacks Equity Research
Companies In The News are: GOOS,FB,RDY,FOXA
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
by Zacks Equity Research
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
BioMarin Begins Pediatric Study on Achondroplasia Candidate
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Pharma Stocks Weighed Down by Competition, Generic Pressure
by Zacks Equity Research
Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
by Zacks Equity Research
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Teva Reintroduces Generic Depo-Provera Injection in U.S.
by Zacks Equity Research
Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.
Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher
by Zacks Equity Research
Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
by Zacks Equity Research
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
VIVUS Settles with Teva on Weight Management Drug Generic
by Zacks Equity Research
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
Pricing, Competition Remain Headwinds for Pharma in 2017
by Arpita Dutt
Fears regarding the drug pricing issue have waned, it will nevertheless remain a headwind in the near term.
New Strong Sell Stocks for April 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Mylan Down on FDA Warning Letter to Manufacturing Facility
by Zacks Equity Research
Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
New Strong Sell Stocks for April 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: